HomeQuestion

How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?

1

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Would you use T-DXd as a first-line agent for a patient who developed early metastatic relapse of HER2+ urothelial cancer shortly after standard perioperative chemo/immunotherapy, over other standard non-targeted treatments?

Would you consider utilizing pembrolizumab/enfortumab as a bladder preservation approach in patients with MIBC?

Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?

Do you get DEXA scans routinely before starting ADT for prostate cancer or endocrine therapy for breast cancer?

In patients with muscle-invasive bladder cancer, in what clinical scenarios would you consider neoadjuvant cisplatin-based therapy in light of emerging data on enfortumab vedotin plus pembrolizumab?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.